Pharmacokinetic profiles of anticancer herbal medicines in humans and the clinical implications

Current Medicinal Chemistry

Volumn 18, Issue 21, 2011, Pages 3190-3210

  Chen, X W ^a   Sneed, K B ^b   Zhou, S F ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anticancer herbal medicine; Curcumin; Ginkgo; Ginseng; Grape seed; Herb drug interaction; Huangqin; Milk thistle; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; ARISTOLOCHIC ACID; ARSENIC TRIOXIDE; BILOBALIDE; CALLILEPIS LAUREOLA EXTRACT; CATECHIN; CISPLATIN; CURCUMIN; DEXAMETHASONE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; GINGER EXTRACT; GINGEROL; GINKGO BILOBA EXTRACT; GINKGOLIDE B; GINKOLIDE A; GINSENG EXTRACT; HERBACEOUS AGENT; HUANGQIN; HYPERICUM PERFORATUM EXTRACT; IMATINIB; METOCLOPRAMIDE; ONDANSETRON; PLACEBO; RESVERATROL; SHOGAOL; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILYBUM MARIANUM EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL EVALUATION; COLORECTAL CARCINOMA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; GENOTOXICITY; HUMAN; IMMUNE RESPONSE; KIDNEY INJURY; LIVER INJURY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN PRURITUS; STOMACH CANCER; TISSUE DISTRIBUTION; TOXICOKINETICS; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; HERB-DRUG INTERACTIONS; HUMANS; NEOPLASMS; PHYTOTHERAPY; PLANTS, MEDICINAL;

EID: 79959946622     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796391624     Document Type: Article

References (236)

1. Lin, J. H.; Yamazaki, M., Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003, 42, 59-98. (Pubitemid 36092258)
2. Lin, J. H.; Lu, A. Y. H., Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 1997, 49, 403-449. (Pubitemid 28030947)
3. Dai, Z.; Cui, G.; Zhou, S. F.; Zhang, X.; Huang, L., Cloning and characterization of a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase gene from Salvia miltiorrhiza involved in diterpenoid tanshinone accumulation. J Plant Physiol. 2011, 168, 148-157.
4. He, S. M.; Zhou, Z. W.; Li, X. T.; Zhou, S. F., Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr Med Chem. 2011, 18, 667-713.
5. Xiong, Y.; Zhou, S. F.; Zhou, R.; Yang, D.; Xu, Z. F.; Lou, Y. T.; Guo, Q. S.; Hu, R.; Peng, T.; Ma, D.; Li, X. T., Alternations of Maternal and Cord Plasma Hemostasis in Preeclampsia Before and After Delivery. Hypertens Pregnancy, 2011, [epub ahead of print].
6. Prentis, R. A.; Lis, Y.; Walker, S. R., Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol. 1988, 25, 387-396.
7. Stone, R., Biochemistry. Lifting the veil on traditional Chinese medicine. Science. 2008, 319, 709-710. (Pubitemid 351225838)
8. Patwardhan, B.; Vaidya, A. D., Natural products drug discovery: accelerating the clinical candidate development using reverse pharmacology approaches. Indian J Exp Biol. 2010, 48, 220-227.
9. Engdal, S.; Klepp, O.; Nilsen, O. G., Identification and exploration of herbdrug combinations used by cancer patients. Integr Cancer Ther. 2009, 8, 29-36.
10. Ernst, E.; Cassileth, B. R., The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998, 83, 777-782. (Pubitemid 28387704)
11. Sparreboom, A.; Cox, M. C.; Acharya, M. R.; Figg, W. D., Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004, 22, 2489-2503. (Pubitemid 41115408)
12. Warshafsky, S.; Kamer, R. S.; Sivak, S. L., Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med. 1993, 119, 599-605. (Pubitemid 23311262)
13. Werneke, U.; Earl, J.; Seydel, C.; Horn, O.; Crichton, P.; Fannon, D., Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer. 2004, 90, 408-413. (Pubitemid 38250637)
14. MacLennan, A. H.; Wilson, D. H.; Taylor, A. W., The escalating cost and prevalence of alternative medicine. Prev Med. 2002, 35, 166-173.
15. Hu, Z.; Yang, X.; Ho, P. C.; Chan, S. Y.; Heng, P. W.; Chan, E.; Duan, W.; Koh, H. L.; Zhou, S., Herb-drug interactions: a literature review. Drugs. 2005, 65, 1239-1282. (Pubitemid 41038418)
16. Izzo, A. A., Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol. 2005, 19, 1-16. (Pubitemid 40204343)
17. He, S. M.; Li, C. G.; Liu, J. P.; Chan, E.; Duan, W.; Zhou, S. F., Disposition pathways and pharmacokinetics of herbal medicines in humans. Curr Med Chem. 2010, 17, 4072-4113.
18. Jordan, S. A.; Cunningham, D. G.; Marles, R. J., Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol. 2010, 243, 198-216.
19. Vlietinck, A.; Pieters, L.; Apers, S., Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union. Planta Med. 2009, 75, 683-688.
20. Zhou, S. F.; Zhou, Z. W.; Huang, M., Pharmacokinetics and disposition of plant natural products in humans and the clinical and toxicological implications. Curr Org Chem. 2010, 14, 1732-1756.
21. Bhattaram, V. A.; Graefe, U.; Kohlert, C.; Veit, M.; Derendorf, H., Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine. 2002, 9, 1-33. (Pubitemid 41623448)
22. He, S. M.; Chan, E.; Zhou, S. F., ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr Pharm Des. 2011, 17, 357-407.
23. Zhou, S. F.; Xue, C. C.; Yu, X. Q.; Wang, G., Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab. 2007, 8, 526-553. (Pubitemid 47209094)
24. Antman, K. H., Introduction: the history of arsenic trioxide in cancer therapy. Oncologist. 2001, 6 Suppl 2, 1-2. (Pubitemid 32405842)
25. Liu, J.; Lu, Y.; Wu, Q.; Goyer, R. A.; Waalkes, M. P., Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther. 2008, 326, 363-368.
26. Niu, C.; Yan, H.; Yu, T.; Sun, H. P.; Liu, J. X.; Li, X. S.; Wu, W.; Zhang, F. Q.; Chen, Y.; Zhou, L.; Li, J. M.; Zeng, X. Y.; Yang, R. R.; Yuan, M. M.; Ren, M. Y.; Gu, F. Y.; Cao, Q.; Gu, B. W.; Su, X. Y.; Chen, G. Q.; Xiong, S. M.; Zhang, T. D.; Waxman, S.; Wang, Z. Y.; Chen, Z.; Hu, J.; Shen, Z. X.; Chen, S. J., Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999, 94, 3315-3324. (Pubitemid 29536124)
27. Shen, Z. X.; Chen, G. Q.; Ni, J. H.; Li, X. S.; Xiong, S. M.; Qiu, Q. Y.; Zhu, J.; Tang, W.; Sun, G. L.; Yang, K. Q.; Chen, Y.; Zhou, L.; Fang, Z. W.; Wang, Y. T.; Ma, J.; Zhang, P.; Zhang, T. D.; Chen, S. J.; Chen, Z.; Wang, Z. Y., Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997, 89, 3354-3360.
28. Zhang, P.; Wang, S. Y.; Hu, X., H., Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol. 1996, 17, 58-62.
29. Soignet, S. L.; Maslak, P.; Wang, Z. G.; Jhanwar, S.; Calleja, E.; Dardashti, L. J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D. A.; Pandolfi, P. P.; Warrell, R. P., Jr., Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998, 339, 1341-1348. (Pubitemid 28509343)
30. Zhang, T. D.; Chen, G. Q.; Wang, Z. G.; Wang, Z. Y.; Chen, S. J.; Chen, Z., Arsenic trioxide, a therapeutic agent for APL. Oncogene. 2001, 20, 7146-7153. (Pubitemid 33105004)
31. Chen, G. Q.; Zhou, L.; Styblo, M.; Walton, F.; Jing, Y.; Weinberg, R.; Chen, Z.; Waxman, S., Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 2003, 63, 1853-1859. (Pubitemid 36460848)
32. Aposhian, H. V.; Zakharyan, R. A.; Avram, M. D.; Sampayo-Reyes, A.; Wollenberg, M. L., A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species. Toxicol Appl Pharmacol. 2004, 198, 327-335. (Pubitemid 38969962)
33. Fujisawa, S.; Ohno, R.; Shigeno, K.; Sahara, N.; Nakamura, S.; Naito, K.; Kobayashi, M.; Shinjo, K.; Takeshita, A.; Suzuki, Y.; Hashimoto, H.; Kinoshita, K.; Shimoya, M.; Kaise, T.; Ohnishi, K., Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol. 2007, 59, 485-493. (Pubitemid 46122327)
34. Wang, Z.; Zhou, J.; Lu, X.; Gong, Z.; Le, X. C., Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol. 2004, 17, 95-103. (Pubitemid 38134064)
35. Sweeney, C. J.; Takimoto, C.; Wood, L.; Porter, J. M.; Tracewell, W. G.; Darwish, M.; D'Andrea, D. M.; Remick, S. C., A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010, 66, 345-356.
36. Chen, D.; Wan, S. B.; Yang, H.; Yuan, J.; Chan, T. H.; Dou, Q. P., EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem. 2011, 53, 155-177.
37. Yang, C. S.; Wang, X., Green tea and cancer prevention. Nutr Cancer. 2010, 62, 931-937.
38. Bell, J. R.; Donovan, J. L.; Wong, R.; Waterhouse, A. L.; German, J. B.; Walzem, R. L.; Kasim-Karakas, S. E., (+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. Am J Clin Nutr. 2000, 71, 103-108. (Pubitemid 30033591)
39. Goldberg, D. M.; Yan, J.; Soleas, G. J., Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003, 36, 79-87. (Pubitemid 36126394)
40. Ullmann, U.; Haller, J.; Decourt, J. P.; Girault, N.; Girault, J.; Richard-Caudron, A. S.; Pineau, B.; Weber, P., A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res. 2003, 31, 88-101. (Pubitemid 36553307)
41. Henning, S. M.; Niu, Y.; Liu, Y.; Lee, N. H.; Hara, Y.; Thames, G. D.; Minutti, R. R.; Carpenter, C. L.; Wang, H.; Heber, D., Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem. 2005, 16, 610-616. (Pubitemid 41338373)
42. Unno, T.; Sagesaka, Y. M.; Kakuda, T., Analysis of tea catechins in human plasma by high-performance liquid chromatography with solid-phase extraction. J Agric Food Chem. 2005, 53, 9885-9889. (Pubitemid 43081193)
43. Kundu, J. K.; Na, H. K.; Surh, Y. J., Ginger-derived phenolic substances with cancer preventive and therapeutic potential. Forum Nutr. 2009, 61, 182-192.
44. Nicoll, R.; Henein, M. Y., Ginger (Zingiber officinale Roscoe): a hot remedy for cardiovascular disease? Int J Cardiol. 2009, 131, 408-409.
45. Ali, B. H.; Blunden, G.; Tanira, M. O.; Nemmar, A., Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008, 46, 409-420. (Pubitemid 350297543)
46. Manusirivithaya, S.; Sripramote, M.; Tangjitgamol, S.; Sheanakul, C.; Leelahakorn, S.; Thavaramara, T.; Tangcharoenpanich, K., Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer. 2004, 14, 1063-1069. (Pubitemid 39603348)
47. Hickok, J. T.; Roscoe, J. A.; Morrow, G. R.; Ryan, J. L., A Phase II/III randomized, placebo-controlled, double-blind clinical trial of ginger (Zingiber officinale) for nausea caused by chemotherapy for cancer: a currently accruing URCC CCOP cancer control study. Support Cancer Ther. 2007, 4, 247-250. (Pubitemid 47606352)
48. Pillai, A. K.; Sharma, K. K.; Gupta, Y. K.; Bakhshi, S., Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer. 2011, 56, 234-238.
49. Zick, S. M.; Djuric, Z.; Ruffin, M. T.; Litzinger, A. J.; Normolle, D. P.; Alrawi, S.; Feng, M. R.; Brenner, D. E., Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008, 17, 1930-1936.
50. Ahmed, R. S.; Seth, V.; Pasha, S. T.; Banerjee, B. D., Influence of dietary ginger (Zingiber officinales Rosc) on oxidative stress induced by malathion in rats. Food Chem Toxicol. 2000, 38, 443-450. (Pubitemid 30179734)
51. Nakazawa, T.; Ohsawa, K., Metabolism of [6]-gingerol in rats. Life Sci. 2002, 70, 2165-2175. (Pubitemid 34219466)
52. Hoehle, S. I.; Pfeiffer, E.; Metzler, M., Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases. Mol Nutr Food Res. 2007, 51, 932-938. (Pubitemid 47292266)
53. Kelly, J. P.; Kaufman, D. W.; Kelley, K.; Rosenberg, L.; Anderson, T. E.; Mitchell, A. A., Recent trends in use of herbal and other natural products. Arch Intern Med. 2005, 165, 281-286. (Pubitemid 40216279)
54. van Beek, T. A., Chemical analysis of Ginkgo biloba leaves and extracts. J Chromatogr A. 2002, 967, 21-55. (Pubitemid 34786583)
55. Gurley, B. J.; Gardner, S. F.; Hubbard, M. A.; Williams, D. K.; Gentry, W. B.; Cui, Y.; Ang, C. Y., Cytochrome P450 phenotypic ratios for predicting herbdrug interactions in humans. Clin Pharmacol Ther. 2002, 72, 276-287.
56. Xu, A. H.; Chen, H. S.; Sun, B. C.; Xiang, X. R.; Chu, Y. F.; Zhai, F.; Jia, L. C., Therapeutic mechanism of ginkgo biloba exocarp polysaccharides on gastric cancer. World J Gastroenterol. 2003, 9, 2424-2427. (Pubitemid 37461241)
57. Chen, H. S.; Zhai, F.; Chu, Y. F.; Xu, F.; Xu, A. H.; Jia, L. C., [Clinical study on treatment of patients with upper digestive tract malignant tumors of middle and late stage with Ginkgo biloba exocarp polysaccharides capsule preparation]. Zhong Xi Yi Jie He Xue Bao. 2003, 1, 189-191.
58. Hauns, B.; Haring, B.; Kohler, S.; Mross, K.; Unger, C., Phase II study of combined 5-fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. Phytother Res. 2001, 15, 34-38. (Pubitemid 32155107)
59. Hauns, B.; Haring, B.; Kohler, S.; Mross, K.; Robben-Bathe, P.; Unger, C., Phase II study with 5-fluorouracil and Ginkgo biloba extract (GBE 761 ONC) in patients with pancreatic cancer. Arzneimittelforschung. 1999, 49, 1030-1034. (Pubitemid 30013113)
60. Kleijnen, J.; Knipschild, P., Ginkgo biloba. Lancet. 1992, 340, 1136-1139.
61. Wojcicki, J.; Gawronska-Szklarz, B.; Bieganowski, W.; Patalan, M.; Smulski, H. K.; Samochowiec, L.; Zakrzewski, J., Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers. Mater Med Pol. 1995, 27, 141-146. (Pubitemid 26381189)
62. Fourtillan, J. B.; Brisson, A. M.; Girault, J.; Ingrand, I.; Decourt, J. P.; Drieu, K.; Jouenne, P.; Biber, A., [Pharmacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. Therapie. 1995, 50, 137-144.
63. Mauri, P.; Simonetti, P.; Gardana, C.; Minoggio, M.; Morazzoni, P.; Bombardelli, E.; Pietta, P., Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun Mass Spectrom. 2001, 15, 929-934. (Pubitemid 32587181)
64. Drago, F.; Floriddia, M. L.; Cro, M.; Giuffrida, S., Pharmacokinetics and bioavailability of a Ginkgo biloba extract. J Ocul Pharmacol Ther. 2002, 18, 197-202. (Pubitemid 34297302)
65. Kressmann, S.; Biber, A.; Wonnemann, M.; Schug, B.; Blume, H. H.; Muller, W. E., Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol. 2002, 54, 1507-1514. (Pubitemid 35331212)
66. Wang, F. M.; Yao, T. W.; Zeng, S., Determination of quercetin and kaempferol in human urine after orally administrated tablet of Ginkgo biloba extract by HPLC. J Pharm Biomed Anal. 2003, 33, 317-321. (Pubitemid 37101449)
67. Nieder, M., Pharmakokinetik der ginkgo flavonole im plasma. Muench Med. 1991, 133, S61-S62.
68. Xiang, Y. Z.; Shang, H. C.; Gao, X. M.; Zhang, B. L., A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res. 2008, 22, 851-858.
69. Lu, J. M.; Yao, Q.; Chen, C., Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol. 2009, 7, 293-302.
70. Nah, S. Y.; Kim, D. H.; Rhim, H., Ginsenosides: are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev. 2007, 13, 381-404. (Pubitemid 350233470)
71. Christensen, L. P., Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res. 2009, 55, 1-99.
72. Chang, Y. S.; Seo, E. K.; Gyllenhaal, C.; Block, K. I., Panax ginseng: a role in cancer therapy? Integr Cancer Ther. 2003, 2, 13-33. (Pubitemid 37101984)
73. Shim, J. Y.; Han, Y.; Ahn, J. Y.; Yun, Y. S.; Song, J. Y, Chemoprotective and adjuvant effects of immunomodulator ginsan in cyclophosphamide-treated normal and tumor bearing mice. Int J Immunopathol Pharmacol. 2007, 20, 487-497. (Pubitemid 47531052)
74. Block, K. I.; Mead, M. N., Immune system effects of echinacea, ginseng, and astragalus: a review. Integr Cancer Ther. 2003, 2, 247-267. (Pubitemid 37138611)
75. Lau, W. S.; Chan, R. Y.; Guo, D. A.; Wong, M. S., Ginsenoside Rg1 exerts estrogen-like activities via ligand-independent activation of ERα pathway. J Steroid Biochem Mol Biol. 2008, 108, 64-71. (Pubitemid 351173825)
76. Shin, H. R.; Kim, J. Y.; Yun, T. K.; Morgan, G.; Vainio, H., The cancerpreventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control. 2000, 11, 565-576. (Pubitemid 30342846)
77. Kim, J. H.; Park, C. Y.; Lee, S. J., Effects of sun ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial. J Clin Pharm Ther. 2006, 31, 331-334.
78. Cui, Y.; Shu, X. O.; Gao, Y. T.; Cai, H.; Tao, M. H.; Zheng, W., Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol. 2006, 163, 645-653.
79. Cui, J. F.; Garle, M.; Bjorkhem, I.; Eneroth, P., Determination of aglycones of ginsenosides in ginseng preparations sold in Sweden and in urine samples from Swedish athletes consuming ginseng. Scand J Clin Lab Invest. 1996, 56, 151-160. (Pubitemid 26122797)
80. Cui, J. F.; Bjorkhem, I.; Eneroth, P., Gas chromatographic-mass spectrometric determination of 20 (S)-protopanaxadiol and 20 (S) - protopanaxatriol for study on human urinary excretion of ginsenosides after ingestion of ginseng preparations. J Chromatogr B Biomed Sci Appl. 1997, 689, 349-355. (Pubitemid 27091361)
81. Hasegawa, H.; Sung, J. H.; Matsumiya, S.; Uchiyama, M., Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med. 1996, 62, 453-457. (Pubitemid 26370341)
82. Lee, J.; Lee, E.; Kim, D.; Yoo, J.; Koh, B., Studies on absorption, distribution and metabolism of ginseng in humans after oral administration. J Ethnopharmacol. 2009, 122, 143-148.
83. Yang, L.; Xu, S. J.; Wu, Z. F.; Liu, Y. M.; Zeng, X., Determination of ginsenoside-Rg (1) in human plasma and its application to pharmacokinetic studies following intravenous administration of 'Shenmai' injection. Phytother Res. 2009, 23, 65-71.
84. Guerrero, R. F.; Garcia-Parrilla, M. C.; Puertas, B.; Cantos-Villar, E., Wine, resveratrol and health: a review. Nat Prod Commun. 2009, 4, 635-658.
85. Gupta, S. C.; Kannappan, R.; Reuter, S.; Kim, J. H.; Aggarwal, B. B., Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci. 2011, 1215, 150-160.
86. Ndiaye, M.; Kumar, R.; Ahmad, N., Resveratrol in cancer management: where are we and where we go from here? Ann N Y Acad Sci. 2011, 1215, 144-149.
87. Szekeres, T.; Saiko, P.; Fritzer-Szekeres, M.; Djavan, B.; Jager, W., Chemopreventive effects of resveratrol and resveratrol derivatives. Ann N Y Acad Sci. 2011, 1215, 89-95.
88. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E., Jr.; Walle, U. K., High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004, 32, 1377-1382. (Pubitemid 39564557)
89. Wenzel, E.; Somoza, V., Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005, 49, 472-481. (Pubitemid 40780394)
90. Boocock, D. J.; Faust, G. E.; Patel, K. R.; Schinas, A. M.; Brown, V. A.; Ducharme, M. P.; Booth, T. D.; Crowell, J. A.; Perloff, M.; Gescher, A. J.; Steward, W. P.; Brenner, D. E., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007, 16, 1246-1252. (Pubitemid 46984966)
91. Vaz-da-Silva, M.; Loureiro, A. I.; Falcao, A.; Nunes, T.; Rocha, J. F.; Fernandes-Lopes, C.; Soares, E.; Wright, L.; Almeida, L.; Soares-da-Silva, P., Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther. 2008, 46, 564-570.
92. Vitaglione, P.; Sforza, S.; Galaverna, G.; Ghidini, C.; Caporaso, N.; Vescovi, P. P.; Fogliano, V.; Marchelli, R., Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 2005, 49, 495-504. (Pubitemid 40780396)
93. Li-Weber, M., New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents wogonin, baicalein and baicalin. Cancer Treat Rev. 2009, 35, 57-68.
94. Kowalczyk, E.; Krzesinski, P.; Kura, M.; Niedworok, J.; Kowalski, J.; Blaszczyk, J., [Pharmacological effects of flavonoids from Scutellaria baicalensis]. Przegl Lek. 2006, 63, 95-96.
95. Lai, M. Y.; Hsiu, S. L.; Chen, C. C.; Hou, Y. C.; Chao, P. D., Urinary pharmacokinetics of baicalein, wogonin and their glycosides after oral administration of Scutellariae Radix in humans. Biol Pharm Bull. 2003, 26, 79-83.
96. Akao, T.; Kawabata, K.; Yanagisawa, E.; Ishihara, K.; Mizuhara, Y.; Wakui, Y.; Sakashita, Y.; Kobashi, K., Baicalin, the predominant flavone glucuronide of Scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol. 2000, 52, 1563-1568. (Pubitemid 32058657)
97. Abe, K.; Inoue, O.; Yumioka, E., Biliary excretion of metabolites of baicalin and baicalein in rats. Chem Pharm Bull (Tokyo). 1990, 38, 209-211.
98. Kroll, D. J.; Shaw, H. S.; Oberlies, N. H., Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007, 6, 110-119. (Pubitemid 46871844)
99. Pradhan, S. C.; Girish, C., Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006, 124, 491-504. (Pubitemid 46157708)
100. Das, S. K.; Vasudevan, D. M., Protective effects of silymarin, a milk thistle (Silybium marianum) derivative on ethanol-induced oxidative stress in liver. Indian J Biochem Biophys. 2006, 43, 306-311.
101. Comelli, M. C.; Mengs, U.; Schneider, C.; Prosdocimi, M., Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther. 2007, 6, 120-129. (Pubitemid 46871849)
102. Sagar, S. M., Future directions for research on Silybum marianum for cancer patients. Integr Cancer Ther. 2007, 6, 166-173. (Pubitemid 46871841)
103. Tamayo, C.; Diamond, S., Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther. 2007, 6, 146-157. (Pubitemid 46871845)
104. Wallace, S.; Carrier, D.; Clausen, E., Extraction of nutraceuticals from milk thistle: Part II. Extraction with organic solvents. Appl Biochem Biotechnol. 2003, 108, 891-904. (Pubitemid 36535220)
105. Kvasnicka, F.; Biba, B.; Sevcik, R.; Voldrich, M.; Kratka, J., Analysis of the active components of silymarin. J Chromatogr A. 2003, 990, 239-245. (Pubitemid 36293880)
106. Mansour, H. H.; Hafez, H. F.; Fahmy, N. M., Silymarin modulates cisplatininduced oxidative stress and hepatotoxicity in rats. J Biochem Mol Biol. 2006, 39, 656-661. (Pubitemid 44892889)
107. Gaedeke, J.; Fels, L. M.; Bokemeyer, C.; Mengs, U.; Stolte, H.; Lentzen, H., Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant. 1996, 11, 55-62. (Pubitemid 26038465)
108. Karimi, G.; Ramezani, M.; Tahoonian, Z., Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med. 2005, 2, 383-386. (Pubitemid 41253351)
109. Singh, R. P.; Raina, K.; Deep, G.; Chan, D.; Agarwal, R., Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res. 2009, 15, 613-621.
110. Singh, R. P.; Raina, K.; Sharma, G.; Agarwal, R., Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 2008, 14, 7773-7780.
111. Singh, R. P.; Tyagi, A.; Sharma, G.; Mohan, S.; Agarwal, R., Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving downregulation of survivin. Clin Cancer Res. 2008, 14, 300-308. (Pubitemid 351378006)
112. Raina, K.; Rajamanickam, S.; Singh, R. P.; Deep, G.; Chittezhath, M.; Agarwal, R., Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008, 68, 6822-6830.
113. Gallo, D.; Giacomelli, S.; Ferlini, C.; Raspaglio, G.; Apollonio, P.; Prislei, S.; Riva, A.; Morazzoni, P.; Bombardelli, E.; Scambia, G., Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur J Cancer. 2003, 39, 2403-2410. (Pubitemid 37214866)
114. Flaig, T. W.; Gustafson, D. L.; Su, L. J.; Zirrolli, J. A.; Crighton, F.; Harrison, G. S.; Pierson, A. S.; Agarwal, R.; Glode, L. M., A Phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007, 25, 139-146. (Pubitemid 46020872)
115. Kidd, P.; Head, K., A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev. 2005, 10, 193-203. (Pubitemid 41384033)
116. Hoh, C.; Boocock, D.; Marczylo, T.; Singh, R.; Berry, D. P.; Dennison, A. R.; Hemingway, D.; Miller, A.; West, K.; Euden, S.; Garcea, G.; Farmer, P. B.; Steward, W. P.; Gescher, A. J., Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res. 2006, 12, 2944-2950.
117. Schroder, F. H.; Roobol, M. J.; Boeve, E. R.; de Mutsert, R.; Zuijdgeest-van Leeuwen, S. D.; Kersten, I.; Wildhagen, M. F.; van Helvoort, A., Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol. 2005, 48, 922-930; discussion 930-921. (Pubitemid 41641637)
118. Wen, Z.; Dumas, T. E.; Schrieber, S. J.; Hawke, R. L.; Fried, M. W.; Smith, P. C., Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos. 2008, 36, 65-72.
119. Kim, Y. C.; Kim, E. J.; Lee, E. D.; Kim, J. H.; Jang, S. W.; Kim, Y. G.; Kwon, J. W.; Kim, W. B.; Lee, M. G., Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther. 2003, 41, 593-596. (Pubitemid 37527566)
120. Barzaghi, N.; Crema, F.; Gatti, G.; Pifferi, G.; Perucca, E., Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet. 1990, 15, 333-338.
121. Li, W.; Gao, J.; Zhao, H. Z.; Liu, C. X., Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2006, 31, 265-270.
122. Gatti, G.; Perucca, E., Plasma concentrations of free and conjugated silybin after oral intake of a silyb in-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther. 1994, 32, 614-617. (Pubitemid 24336552)
123. Weyhenmeyer, R.; Mascher, H.; Birkmayer, J., Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol. 1992, 30, 134-138.
124. Wu, J. W.; Lin, L. C.; Tsai, T. H., Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol. 2009, 121, 185-193.
125. Schrieber, S. J.; Wen, Z.; Vourvahis, M.; Smith, P. C.; Fried, M. W.; Kashuba, A. D.; Hawke, R. L., The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos. 2008, 36, 1909-1916.
126. Kren, V.; Ulrichova, J.; Kosina, P.; Stevenson, D.; Sedmera, P.; Prikrylova, V.; Halada, P.; Simanek, V., Chemoenzymatic preparation of silybin β-glucuronides and their biological evaluation. Drug Metab Dispos. 2000, 28, 1513-1517.
127. Lorenz, D.; Lucker, P. W.; Mennicke, W. H.; Wetzelsberger, N., Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol. 1984, 6, 655-661. (Pubitemid 15217352)
128. Flory, P. J.; Krug, G.; Lorenz, D.; Mennicke, W. H., [Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose]. Planta Med. 1980, 38, 227-237. (Pubitemid 10065824)
129. Lorenz, D.; Mennicke, W. H.; Behrendt, W., [Elimination of silymarin by cholecystectomied patients. 2. Biliary elimination after multiple oral doses]. Planta Med. 1982, 45, 216-223. (Pubitemid 12035793)
130. Jancova, P.; Anzenbacherova, E.; Papouskova, B.; Lemr, K.; Luzna, P.; Veinlichova, A.; Anzenbacher, P.; Simanek, V., Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos. 2007, 35, 2035-2039. (Pubitemid 350005192)
131. Beckmann-Knopp, S.; Rietbrock, S.; Weyhenmeyer, R.; Bocker, R. H.; Beckurts, K. T.; Lang, W.; Hunz, M.; Fuhr, U., Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol. 2000, 86, 250-256. (Pubitemid 30413400)
132. Sridar, C.; Goosen, T. C.; Kent, U. M.; Williams, J. A.; Hollenberg, P. F., Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 2004, 32, 587-594. (Pubitemid 38668150)
133. Wongcharoen, W.; Phrommintikul, A., The protective role of curcumin in cardiovascular diseases. Int J Cardiol. 2009, 133, 145-151.
134. Aggarwal, B. B.; Sung, B., Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci. 2009, 30, 85-94.
135. Aggarwal, B. B.; Harikumar, K. B., Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009, 41, 40-59.
136. Goel, A.; Kunnumakkara, A. B.; Aggarwal, B. B., Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008, 75, 787-809.
137. Anand, P.; Thomas, S. G.; Kunnumakkara, A. B.; Sundaram, C.; Harikumar, K. B.; Sung, B.; Tharakan, S. T.; Misra, K.; Priyadarsini, I. K.; Rajasekharan, K. N.; Aggarwal, B. B., Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol. 2008, 76, 1590-1611.
138. Lopez-Lazaro, M., Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008, 52 Suppl 1, S103-127.
139. Wang, Y. J.; Pan, M. H.; Cheng, A. L.; Lin, L. I.; Ho, Y. S.; Hsieh, C. Y.; Lin, J. K., Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997, 15, 1867-1876.
140. Begum, A. N.; Jones, M. R.; Lim, G. P.; Morihara, T.; Kim, P.; Heath, D. D.; Rock, C. L.; Pruitt, M. A.; Yang, F.; Hudspeth, B.; Hu, S.; Faull, K. F.; Teter, B.; Cole, G. M.; Frautschy, S. A., Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther. 2008, 326, 196-208. (Pubitemid 351872144)
141. Garcea, G.; Jones, D. J.; Singh, R.; Dennison, A. R.; Farmer, P. B.; Sharma, R. A.; Steward, W. P.; Gescher, A. J.; Berry, D. P., Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer. 2004, 90, 1011-1015. (Pubitemid 38499692)
142. Ireson, C.; Orr, S.; Jones, D. J.; Verschoyle, R.; Lim, C. K.; Luo, J. L.; Howells, L.; Plummer, S.; Jukes, R.; Williams, M.; Steward, W. P.; Gescher, A., Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001, 61, 1058-1064. (Pubitemid 32174425)
143. Tamvakopoulos, C.; Dimas, K.; Sofianos, Z. D.; Hatziantoniou, S.; Han, Z.; Liu, Z. L.; Wyche, J. H.; Pantazis, P., Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res. 2007, 13, 1269-1277. (Pubitemid 46424068)
144. Sakano, K.; Kawanishi, S., Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch Biochem Biophys. 2002, 405, 223-230. (Pubitemid 35191736)
145. Ireson, C. R.; Jones, D. J.; Orr, S.; Coughtrie, M. W.; Boocock, D. J.; Williams, M. L.; Farmer, P. B.; Steward, W. P.; Gescher, A. J., Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev. 2002, 11, 105-111. (Pubitemid 34118319)
146. Hsu, C. H.; Cheng, A. L., Clinical studies with curcumin. Adv Exp Med Biol. 2007, 595, 471-480.
147. Sharma, R. A.; Steward, W. P.; Gescher, A. J., Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007, 595, 453-470.
148. Sharma, R. A.; Euden, S. A.; Platton, S. L.; Cooke, D. N.; Shafayat, A.; Hewitt, H. R.; Marczylo, T. H.; Morgan, B.; Hemingway, D.; Plummer, S. M.; Pirmohamed, M.; Gescher, A. J.; Steward, W. P., Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004, 10, 6847-6854. (Pubitemid 39383033)
149. Dhillon, N.; Aggarwal, B. B.; Newman, R. A.; Wolff, R. A.; Kunnumakkara, A. B.; Abbruzzese, J. L.; Ng, C. S.; Badmaev, V.; Kurzrock, R, Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008, 14, 4491-4499.
150. Somasundaram, S.; Edmund, N. A.; Moore, D. T.; Small, G. W.; Shi, YY.; Orlowski, R. Z., Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002, 62, 3868-3875. (Pubitemid 34728874)
151. Kessler, D. A., Cancer and herbs. N Engl J Med. 2000, 342, 1742-1743. (Pubitemid 30354523)
152. Bensoussan, A.; Myers, S. P.; Drew, A. K.; Whyte, I. M.; Dawson, A. H., Development of a Chinese herbal medicine toxicology database. J Toxicol Clin Toxicol. 2002, 40, 159-167. (Pubitemid 34755582)
153. Stedman, C, Herbal hepatotoxicity. Semin Liver Dis. 2002, 22, 195-206. (Pubitemid 34496472)
154. McRae, C. A.; Agarwal, K.; Mutimer, D.; Bassendine, M. F., Hepatitis associated with Chinese herbs. Eur J Gastroenterol Hepatol. 2002, 14, 559-562. (Pubitemid 34518190)
155. Ernst, E., Adverse effects of herbal drugs in dermatology. Br J Dermatol. 2000, 143, 923-929.
156. Villegas, J. F.; Barabe, D. N.; Stein, R. A.; Lazar, E., Adverse effects of herbal treatment of cardiovascular disease: what the physician must know. Heart Dis. 2001, 3, 169-175. (Pubitemid 33131470)
157. Greensfelder, L., Alternative medicine. Herbal product linked to cancer. Science. 2000, 288, 1946.
158. Haller, C. A.; Benowitz, N. L., Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000, 343, 1833-1838. (Pubitemid 32104128)
159. Zaacks, S. M.; Klein, L.; Tan, CD.; Rodriguez, E. R.; Leikin, J. B., Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol. 1999, 37, 485-489. (Pubitemid 29387893)
160. Leung, A. Y. Traditional toxicity documentation of Chinese Materia Medica - an overview. Toxicol Pathol. 2006, 34, 319-326.
161. Stickel, F.; Patsenker, E.; Schuppan, D., Herbal hepatotoxicity. J Hepatol. 2005, 43, 901-910. (Pubitemid 41414517)
162. Colson, C. R.; De Broe, M. E., Kidney injury from alternative medicines. Adv Chronic Kidney Dis. 2005, 12, 261-275. (Pubitemid 40922860)
163. Blowey, D. L., Nephrotoxicity of over-the-counter analgesics, natural medicines, and illicit drugs. Adolesc Med Clin. 2005, 16, 31-43. (Pubitemid 40018562)
164. Jha, V., Herbal medicines and chronic kidney disease. Nephrology (Carlton). 2010, 15 Suppl 2, 10-17.
165. Wojcikowski, K.; Johnson, D. W.; Gobe, G., Medicinal herbal extracts - renal friend or foe? Part one: the toxicities of medicinal herbs. Nephrology (Carlton). 2004, 9, 313-318. (Pubitemid 39576935)
166. Seedat, Y. K.; Nathoo, B. C., Acute renal failure in blacks and Indians in South Africa-comparison after 10 years. Nephron. 1993, 64, 198-201. (Pubitemid 23153046)
167. Wainwright, J.; Schonland, M. M., Toxic hepatitis in black patients in natal. S Afr Med J. 1977, 51, 571-573. (Pubitemid 8089726)
168. Watson, A. R.; Coovadia, H. M.; Bhoola, K. D., The clinical syndrome of Impila (Callilepis laureola) poisoning in children. S Afr Med J. 1979, 55, 290-292. (Pubitemid 9139038)
169. Luyckx, V. A.; Ballantine, R.; Claeys, M.; Cuyckens, F.; Van den Heuvel, H.; Cimanga, R. K.; Vlietinck, A. J.; De Broe, M. E.; Katz, I. J., Herbal remedyassociated acute renal failure secondary to Cape aloes. Am J Kidney Dis. 2002, 39, E13.
170. Hilepo, J. N.; Bellucci, A. G.; Mossey, R. T., Acute renal failure caused by 'cat's claw' herbal remedy in a patient with systemic lupus erythematosus. Nephron. 1997, 77, 361. (Pubitemid 27477700)
171. Lindsay, J., Renal failure after eating "magic" mushrooms. CMAJ. 1993, 148, 492. (Pubitemid 23087081)
172. Amitai, I.; Peleg, O.; Ariel, I.; Binyamini, N., Severe poisoning in a child by the mushroom Inocybe tristis, Malencon and Bertault. Isr J Med Sci. 1982, 18, 798-801.
173. Grossman, C. M.; Malbin, B., Mushroom poisoning: a review of the literature and report of two cases caused by a previously undescribed species. Ann Intern Med. 1954, 40, 249-259.
174. Segasothy, M.; Swaminathan, M.; Kong, N. C.; Bennett, W. M., Djenkol bean poisoning (djenkolism): an unusual cause of acute renal failure. Am J Kidney Dis. 1995, 25, 63-66.
175. Li, Y. J.; Lin, J. L.; Yang, C. W.; Yu, C. C., Acute renal failure induced by a Brazilian variety of propolis. Am J Kidney Dis. 2005, 46, e125-129.
176. Stickel, F.; Schuppan, D., Herbal medicine in the treatment of liver diseases. Dig Liver Dis. 2007, 39, 293-304. (Pubitemid 46432239)
177. Stickel, F.; Seitz, H. K.; Hahn, E. G.; Schuppan, D., Hepatotoxicity of herbal remedies. Zeitschrift fur Gastroenterologie. 2001, 39, 225+.
178. Nadir, A.; Agrawal, S.; King, P. D.; Marshall, J. B., Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol. 1996, 91, 1436-1438.
179. Hutchins, G. M., Ma huang toxicity. Mayo Clin Proc. 2002, 77, 733.
180. Borum, M. L., Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol. 2001, 96, 1654-1655. (Pubitemid 32455119)
181. Castot, A.; Larrey, D., Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance. Gastroenterol Clin Biol. 1992, 16, 916-922.
182. Ben Yahia, M.; Mavier, P.; Metreau, J. M.; Zafrani, E. S.; Fabre, M.; Gatineau-Saillant, G.; Dhumeaux, D.; Mallat, A., [Chronic active hepatitis and cirrhosis induced by wild germander. 3 cases]. Gastroenterol Clin Biol. 1993, 17, 959-962. (Pubitemid 24049212)
183. Dao, T.; Peytier, A.; Galateau, F.; Valla, A., [Chronic cirrhogenic hepatitis induced by germander]. Gastroenterol Clin Biol. 1993, 17, 609-610. (Pubitemid 23314604)
184. Laliberte, L.; Villeneuve, J. P., Hepatitis after the use of germander, a herbal remedy. CMAJ. 1996, 154, 1689-1692. (Pubitemid 26178864)
185. Larrey, D.; Vial, T.; Pauwels, A.; Castot, A.; Biour, M.; David, M.; Michel, H., Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med. 1992, 117, 129-132.
186. Mattei, A.; Bizollon, T.; Charles, J. D.; Debat, P.; Fontanges, T.; Chevallier, M.; Trepo, C., Liver damage induced by the ingestion of a product of phytotherapy containing wild germander. Four cases. Gastroenterol Clin Biol. 1992, 16, 798-800.
187. Dourakis, S. P.; Papanikolaou, I. S.; Tzemanakis, E. N.; Hadziyannis, S. J., Acute hepatitis associated with herb (Teucrium capitatum L.) administration. Eur J Gastroenterol Hepatol. 2002, 14, 693-695. (Pubitemid 34666650)
188. Woolf, G. M.; Petrovic, L. M.; Rojter, S. E.; Wainwright, S.; Villamil, F. G.; Katkov, W. N.; Michieletti, P.; Wanless, I. R.; Stermitz, F. R.; Beck, J. J., Acute hepatitis associated with the Chinese herbal product, Jin Bu Huan. Ann Inter Med. 1994, 121, 729-735.
189. Horowitz, R. S.; Feldhaus, K.; Dart, R. C.; Stermitz, F. R.; Beck, J. J., The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med. 1996, 156, 899-903. (Pubitemid 26120595)
190. Picciotto, A.; Campo, N.; Brizzolara, R.; Giusto, R.; Guido, G.; Sinelli, N.; Lapertosa, G.; Celle, G., Chronic hepatitis induced by Jin Bu Huan. J Hepatol. 1998, 28, 165-167. (Pubitemid 28122515)
191. Kaptchuk, T. J., Acute hepatitis associated with jin bu huan. Ann Intern Med. 1995, 122, 636.
192. Park, G. J.; Mann, S. P.; Ngu, M. C., Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum. J Gastroenterol Hepatol. 2001, 16, 115-117. (Pubitemid 32120946)
193. Anderson, I. B.; Mullen, W. H.; Meeker, J. E.; Khojasteh-Bakht, S. C.; Oishi, S.; Nelson, S. D.; Blanc, P. D., Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med. 1996, 124, 726-734. (Pubitemid 26117921)
194. Vanherweghem, J. L.; Depierreux, M.; Tielemans, C.; Abramowicz, D.; Dratwa, M.; Jadoul, M.; Richard, C.; Vandervelde, D.; Verbeelen, D.; Vanhaelen-Fastre, R.; et al., Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993, 341, 387-391. (Pubitemid 23048140)
195. Stiborova, M.; Frei, E.; Wiessler, M.; Schmeiser, H. H., Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem Res Toxicol. 2001, 14, 1128-1137. (Pubitemid 32800169)
196. Stiborova, M.; Frei, E.; Sopko, B.; Wiessler, M.; Schmeiser, H. H., Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis. 2002, 23, 617-625. (Pubitemid 34498500)
197. Schmeiser, H. H.; Frei, E.; Wiessler, M.; Stiborova, M., Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis. 1997, 18, 1055-1062. (Pubitemid 28132355)
198. Zhou, S. F.; Koh, H. L.; Gao, Y. H.; Gong, Z. Y.; Lee, E. J. D., Herbal bioactivation: the good, the bad and the ugly. Life Sci. 2004, 74, 935-968. (Pubitemid 37522131)
199. Fugh-Berman, A., Herb-drug interactions. Lancet. 2000, 355, 134-138. (Pubitemid 30068565)
200. Fugh-Berman, A.; Ernst, E., Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol. 2001, 52, 587-595.
201. Izzo, A. A.; Ernst, E., Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009, 69, 1777-1798.
202. Yang, A. K.; He, S. M.; Liu, L.; Liu, J. P.; Wei, M. Q.; Zhou, S. F., Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem. 2010, 17, 1635-1678.
203. Kennedy, D. A.; Seely, D., Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin Drug Saf. 2010, 9, 79-124.
204. Chan, E.; Tan, M.; Xin, J.; Sudarsanam, S.; Johnson, D. E., Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel. 2010, 13, 50-65.
205. Mathijssen, R. H.; Verweij, J.; de Bruijn, P.; Loos, W. J.; Sparreboom, A., Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002, 94, 1247-1249. (Pubitemid 34993875)
206. Frye, R. F.; Fitzgerald, S. M.; Lagattuta, T. F.; Hruska, M. W.; Egorin, M. J., Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004, 76, 323-329. (Pubitemid 39313122)
207. Smith, P.; Bullock, J. M.; Booker, B. M.; Haas, C. E.; Berenson, C. S.; Jusko, W. J., The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy. 2004, 24, 1508-1514. (Pubitemid 39426346)
208. Graziose, R.; Lila, M. A.; Raskin, I., Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods. Curr Drug Discov Technol. 2010, 7, 2-12.
209. Dunn, W. B.; Broadhurst, D. I.; Atherton, H. J.; Goodacre, R.; Griffin, J. L., Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. 2010, 40, 387-426.
210. Nicholson, J. K.; Wilson, I. D., Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov. 2003, 2, 668-676. (Pubitemid 37361770)
211. Lao, Y. M.; Jiang, J. G.; Yan, L., Application of metabonomic analytical techniques in the modernization and toxicology research of traditional Chinese medicine. Br J Pharmacol. 2009, 157, 1128-1141.
212. Qin, F.; Huang, X.; Zhang, H. M.; Ren, P., Pharmacokinetic comparison of puerarin after oral administration of Jiawei-Xiaoyao-San to healthy volunteers and patients with functional dyspepsia: influence of disease state. J Pharm Pharmacol. 2009, 61, 125-129.
213. Barton, D. L.; Soori, G. S.; Bauer, B. A.; Sloan, J. A.; Johnson, P. A.; Figueras, C.; Duane, S.; Mattar, B.; Liu, H.; Atherton, P. J.; Christensen, B.; Loprinzi, C. L., Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer, 2010, 18, 179-187.
214. Taixiang, W.; Munro, A. J.; Guanjian, L., Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005, CD004540.
215. McCulloch, M.; See, C.; Shu, X. J.; Broffman, M.; Kramer, A.; Fan, W. Y.; Gao, J.; Lieb, W.; Shieh, K.; Colford, J. M., Jr., Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006, 24, 419-430. (Pubitemid 46655594)
216. Zhou, L.; Zuo, Z.; Chow, M. S., Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005, 45, 1345-1359. (Pubitemid 41643896)
217. Seely, D.; Kennedy, D. A.; Myers, S. P.; Cheras, P. A.; Lin, D.; Li, R.; Cattley, T.; Brent, P. A.; Mills, E.; Leonard, B. J., In vitro analysis of the herbal compound Essiac. Anticancer Res. 2007, 27, 3875-3882.
218. Zick, S. M.; Sen, A.; Feng, Y.; Green, J.; Olatunde, S.; Boon, H., Trial of Essiac to ascertain its effect in women with breast cancer (TEA-BC). J Altern Complement Med. 2006, 12, 971-980. (Pubitemid 46095125)
219. Cox, M. C.; Low, J.; Lee, J.; Walshe, J.; Denduluri, N.; Berman, A.; Permenter, M. G.; Petros, W. P.; Price, D. K.; Figg, W. D.; Sparreboom, A.; Swain, S. M., Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res. 2006, 12, 4636-4640. (Pubitemid 44297815)
220. Tanaka, S.; Haruma, K.; Yoshihara, M.; Kajiyama, G.; Kira, K.; Amagase, H.; Chayama, K., Aged garlic extract has potential suppressive effect on colorectal adenomas in humans. J Nutr. 2006, 136, 821S-826S. (Pubitemid 43363785)
221. Qin, Z. F.; Wei, P. K.; Li, J., [Effect of kanglaite injection combined with Chinese drug therapy according to syndrome differentiation on quality of life and immune function in patients with advanced lung cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002, 22, 618-619.
222. Busby, L. T.; Jing, J.; Samlowski, W. E.; McGregor, J. R.; Farling, H.; Wheeler, R. H., Phase I and pharmacokinetic study of Kanglaite injection (KLT), a botanical product based on traditional Chinese Medicine. Proc Am Soc Clin Oncol (ASCO) Ann Meet. 2002, 21.
223. Deng, S. G.; Wen, S. B.; Chen, A. L., Clinical observation of Kanglaite injection combined with gemzar and carboplatin in the treatment of middle and late stage NSCLC. Zhejiang Pract Med. 2006, 11, 234-236.
224. Gao, Y. H.; Zhou, S. F.; Jiang, W. Q.; Huang, M.; X. H., D., Effect of Ganopoly, a Ganoderma lucidum polysaccharide extract on the immunological function in advanced-stage cancer patients. Immunol Invest. 2003, 32, 201-215. (Pubitemid 36962040)
225. Wachtel-Galor, S.; Tomlinson, B.; Benzie, I. F., Ganoderma lucidum ("Lingzhi"), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Br J Nutr. 2004, 91, 263-269. (Pubitemid 38263543)
226. Gao, Y. H.; Chen, G. L.; Dai, X. H.; Ye, J. X.; Zhou, S. F., A Phase I/II study of a Ganoderma lucidum extract (Ganopoly) in patients with advanced cancer. Int J Med Mushr. 2002, 4, 207-214.
227. Gao, Y. H.; Dai, X. H.; Chen, G. L.; Ye, J. X.; Zhou, S. F., A radomized, placebo-controlled, multicenter study of Ganoderma lucidum (W. Curt.:Fr.) Lloyd (Aphyllophoromycetideae) polysaccharides (Ganopoly) in patients with advanced lung cancer. Int J Med Mushr. 2003, 5, 383-395.
228. Horneber, M. A.; Bueschel, G.; Huber, R.; Linde, K.; Rostock, M., Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008, CD003297.
229. Ernst, E.; Schmidt, K.; Steuer-Vogt, M. K., Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer. 2003, 107, 262-267. (Pubitemid 37152907)
230. Kienle, G. S.; Berrino, F.; Bussing, A.; Portalupi, E.; Rosenzweig, S.; Kiene, H., Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res. 2003, 8, 109-119.
231. Sood, A.; Barton, D. L.; Bauer, B. A.; Loprinzi, C. L., A critical review of complementary therapies for cancer-related fatigue. Integr Cancer Ther. 2007, 6, 8-13.
232. Lee, Y. J.; Chung, H. Y.; Kwak, H. K.; Yoon, S., The effects of A. senticosus supplementation on serum lipid profiles, biomarkers of oxidative stress, and lymphocyte DNA damage in postmenopausal women. Biochem Biophys Res Commun. 2008, 375, 44-48.
233. Donovan, J. L.; DeVane, C. L.; Chavin, K. D.; Taylor, R. M.; Markowitz, J. S., Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos. 2003, 31, 519-522. (Pubitemid 36444158)
234. Mori, K.; Kondo, T.; Kamiyama, Y.; Kano, Y.; Tominaga, K., Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003, 51, 403-406. (Pubitemid 36649137)
235. Satoh, H.; Ishikawa, H.; Ohtsuka, M.; Sekizawa, K., Japanese herbal medicine in patients with advanced lung cancer: prolongation of survival. J Altern Complement Med. 2002, 8, 107-108. (Pubitemid 34438481)
236. Henning, S. M.; Niu, Y.; Lee, N. H.; Thames, G. D.; Minutti, R. R.; Wang, H.; Go, V. L.; Heber, D., Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement. Am J Clin Nutr. 2004, 80, 1558-1564. (Pubitemid 41103853)